

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100137-PIP01-21-M02) and to the deferral MHRA-100137-PIP01-21-M03

MHRA-100137-PIP01-21-M03

Scope of the Application

Active Substance(s)

LINACLOTIDE

Condition(s)

Treatment of functional constipation

Pharmaceutical Form(s)

Capsule, hard

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

AbbVie Ltd

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, AbbVie Ltd submitted to the licensing authority on 12/09/2024 11:52 BST an application for a Modification

The procedure started on 29/10/2024 10:47 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100137-PIP01-21-M03

Of 21/01/2025 14:37 GMT

On the adopted decision for LINACLOTIDE (MHRA-100137-PIP01-21-M03) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for LINACLOTIDE, Capsule, hard , ORAL USE .

This decision is addressed to AbbVie Ltd , Abbvie House, Vanwall Business Park, Vanwall Road, Maidenhead , UNITED KINGDOM, SL6 4UB

ANNEX I

1. Waiver

1.1 Condition:

Treatment of functional constipation The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 6 months of age Pharmaceutical form(s): Capsule, hard Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of functional constipation

2.2 Indication(s) targeted by the PIP:

Treatment of functional constipation

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 6 months to less than 18 years of age

2.4 Pharmaceutical Form(s):

Capsule, hard

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of capsules for “sprinkles” mode of administration.
Non-Clinical Studies	1	Study 2 (MNP-103-054) A 9-Week Oral Gavage Toxicity Study in Juvenile mice.
Clinical Studies	7	Study 3 (LIN-MD-62) Randomised, double-blind, placebo-controlled, dose-ranging study of Linaclotide in children, aged from 6 years to less than 18 years, with functional constipation. Study 4 (LIN-MD-67) Randomised, double-blind, placebo-controlled, ascending-dose, dose-ranging study of Linaclotide in children, aged from 2 years to less than 6 years, with functional constipation. Study 5 (M21-862) Two-part study with an open ascending, multidose dose-finding part (Part 1) to assess the safety of linaclotide, and a randomised, double-blind, placebo controlled part (Part 2) to evaluate the safety and efficacy of linaclotide in children from 6 months to less than 2 years of age with functional constipation. Study 6 (LIN-MD-64) Randomised, double-blind, placebo-controlled, parallel-group, confirmatory study of Linaclotide in children aged from 6 years to less than 18 years with Functional Constipation. Study 7 (M21-572) Randomised,

		double-blind, placebo-controlled, parallel-group, confirmatory study of Linaclotide in children aged from 2 years to less than 6 years with functional constipation with an open label 24-week on-treatment extension. Study 8 (LIN-MD-66) Open label, long-term safety study of Linaclotide in children aged from 6 years to less than 18 years with Functional Constipation. Study 9 Randomised, double-blind, parallel-group, safety, and efficacy study, of linaclotide versus placebo in children, aged from 6 months to less than 2 years, with functional constipation with a 24 week open-label on treatment extension.
Extrapolation, Modeling & Simulation Studies	0	Not applicable.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/12/2029
Deferral of one or more studies contained in the paediatric investigation plan:	Yes